Condition
UC
Total Trials
2
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
50.0%
1 terminated out of 2 trials
Success Rate
0.0%
-86.6% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results0
Data Visualizations
Phase Distribution
2Total
Early P 1 (1)
P 1 (1)
Trial Status
Recruiting1
Terminated1
Clinical Trials (2)
Showing 2 of 2 trials
NCT07435779Early Phase 1RecruitingPrimary
Autologous CAR-T Cell Therapy for Refractory and Relapsing Ulcerative Colitis: A Single-Center Exploratory Study
NCT02393248Phase 1Terminated
Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)
Showing all 2 trials